

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Miller Laurie A.</u> (Last) (First) (Middle) <u>125 SUMMER STREET</u> (Street) <u>BOSTON MA 02110</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/30/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>HAEMONETICS CORP [HAE]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP, Human Resources</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>8,199⁽¹⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Non-qualified Stock Option (Right to Buy)</u>	<u>(2)</u>	<u>05/18/2028</u>	<u>Common Stock</u>	<u>1,793</u>	<u>56.57</u>	<u>D</u>	
<u>Non-qualified Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>05/18/2027</u>	<u>Common Stock</u>	<u>1,227</u>	<u>103.37</u>	<u>D</u>	
<u>Non-qualified Stock Option (Right to Buy)</u>	<u>(4)</u>	<u>05/14/2026</u>	<u>Common Stock</u>	<u>1,246</u>	<u>98.03</u>	<u>D</u>	
<u>Non-qualified Stock Option (Right to Buy)</u>	<u>(5)</u>	<u>06/11/2025</u>	<u>Common Stock</u>	<u>1,332</u>	<u>93.52</u>	<u>D</u>	

Explanation of Responses:

- 2,662 securities are in the form of unvested restricted stock units ("RSUs") issued pursuant to the Issuer's 2005 Long-Term Incentive Compensation Plan (as amended) or 2019 Long-Term Incentive Compensation Plan. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. 1,347 of such RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant, with shares vesting on various dates between May 2022 and May 2025. 1,315 of such RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant, with shares vesting in June 2022 and June 2023.
- Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- Reflects options granted on May 18, 2020 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- Reflects options granted on May 14, 2019 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.
- Reflects options granted on June 11, 2018 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.

Remarks:

/s/ Michelle Basil,
attorney-in-fact for Ms. Miller
 ** Signature of Reporting Person
09/09/2021
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB

Number.

POWER OF ATTORNEY
For Executing SEC Securities Transaction Forms

Know all persons by these presents that the undersigned hereby constitutes and appoints each of Michelle L. Basil, Thomas V. Powers and Karen Weisel, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Haemonetics Corporation (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder and such other forms as may be required by the United States Securities and Exchange Commission (the "SEC") relating to transactions by the undersigned in securities issued by the Company ("Forms");
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Forms, complete and execute an amendment or amendments thereto, and timely file such Forms with the SEC and any other appropriate governmental authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file the Forms with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused his/her Power of Attorney to be executed as of September 7, 2021.

/s/ Laurie A. Miller

Signature

Laurie A. Miller

Name